-
Hot Watch List: Microsoft Corporation (NASDAQ:MSFT), Actua Corporation (NASDAQ:ACTA), General Electric Company (NYSE:GE), Parker Drilling Co. (NYSE:PKD), HSBC Holdings plc (ADR) (NYSE:HSBC)
Microsoft Corporation (NASDAQ:MSFT) has 3.00% insider ownership while its institutional ownership stands at 73.90%. In last trading activity company’s stock closed at $46.70. Microsoft Corp. (NASDAQ:MSFT) is evaluating a bid for Salesforce.com Inc., after the cloud software provider was approached by another would-be buyer, people with knowledge of the matter said. Actua Corporation (NASDAQ:ACTA) in…
-
Biotechnology Top Losers: Regulus Therapeutics Inc. (NASDAQ:RGLS), Genetic Technologies Limited (NASDAQ:GENE), NanoString Technologies (NASDAQ:NSTG), MediciNova Inc. (NASDAQ:MNOV), Medgenics (NYSEMKT:MDGN)
Regulus Therapeutics Inc. (NASDAQ:RGLS), announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”). On Monday shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) closed at $15.64. Company’s…
-
Biotechnology Top Gainers: Calithera Biosciences (NASDAQ:CALA), EPIRUS Biopharmaceuticals (NASDAQ:EPRS), Coherus Biosciences (NASDAQ:CHRS), Trevena (NASDAQ:TRVN), Cellular Biomedicine Group (NASDAQ:CBMG)
On 30 January, Calithera Biosciences, Inc. (NASDAQ:CALA), announced the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development. He joins the company following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKline (GSK) and Merck. At Calithera, Dr. Orford will be responsible for clinical development of CB-839,…
-
Biotech Active Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Gilead Sciences Inc. (NASDAQ:GILD), MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naive genotype 1 HCV-infected patients. The primary objective of the study is determination…
-
Hot Biotech Movers: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)
On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced its results of operations for the fourth quarter and full year 2014. Total revenues for the fourth quarter of 2014 were $7.3 billion compared to $3.1 billion for the fourth quarter of 2013.On Friday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $97.48. Company’s sales growth for…
-
Biotech Stocks Touched New Lows: Actinium Pharmaceuticals (NYSEMKT:ATNM), Oncothyreon Inc (NASDAQ:ONTY), TRACON Pharmaceuticals (NASDAQ:TCON), Enzymotec (NASDAQ:ENZY), Cleveland BioLabs (NASDAQ:CBLI)
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company’s common stock at a combined price to the public of $4.50. The shares of common stock and warrants will be issued…
-
Biotech Stocks Touched New Highs: Cambrex Corporation. (NYSE:CBM), Biogen Idec Inc. (NASDAQ:BIIB), Coherus Biosciences (NASDAQ:CHRS), ImmuCell (NASDAQ:ICCC), Esperion Therapeutics (NASDAQ:ESPR)
Cambrex Corporation. (NYSE:CBM) reported Fourth quarter 2014 sales increased 25% to $128.8 million from $103.0 million in the same period last year. Full year 2014 sales increased 18%, and 19% excluding the impact of foreign currency. On Friday shares of Cambrex Corporation. (NYSE:CBM) closed at $30.01. Company’s sales growth for last 5 years was 5.00%…
-
Biotech Losers In Spotlight: TrovaGene (NASDAQ:TROV), Actinium Pharmaceuticals (NYSEMKT:ATNM), Ohr Pharmaceutical (NASDAQ:OHRP), Advaxis (NASDAQ:ADXS), Kite Pharma (NASDAQ:KITE)
Trovagene, Inc. (NASDAQ: TROV), announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on…
-
Biotech Gainers in Spotlight: Genetic Technologies Limited (NASDAQ:GENE), Cambrex Corporation. (NYSE:CBM), Portola Pharmaceuticals (NASDAQ:PTLA), Coherus Biosciences (NASDAQ:CHRS), Vericel Corporation (NASDAQ:VCEL)
On 29 January, Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in…
-
Biotech Top Losers: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), Pacific Biosciences of California (NASDAQ:PACB), Celldex Therapeutics (NASDAQ:CLDX), Enanta Pharmaceuticals (NASDAQ:ENTA)
Gilead Sciences Inc. (NASDAQ:GILD) reported Total revenues of $7.3 billion were no comparison to the year-ago figure of $3.1 billion. Quarterly revenues were above the Zacks Consensus Estimate of $6.7 billion. Full-year 2014 revenues increased 122.2% to $24.9 billion, topping the Zacks Consensus Estimate of $24.3 billion. Earnings (including stock-based compensation expenses) increased to $7.91…